Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

Novartis building

Novartis hit by kickback lawsuits in US

Company accused of paying millions of dollars to doctors in exchange for prescribing drugs

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

- PMLiVE

BMS wins wider NICE Orencia arthritis approval

But only after cutting the drug's price

- PMLiVE

Roche faces another NICE rejection for Avastin

Draft guidance turns down drug for use in ovarian cancer

National Institute for Health and Care Excellence NICE logo

Cell Therapeutics fails to gain NICE backing for blood cancer drug

Watchdog says not enough evidence to show Pixuvri is more effective than current treatments

- PMLiVE

Additional NICE recommendation for Novartis’ Lucentis

Says drug can be used in patients with macular oedema caused by blockage of the veins in the retina

- PMLiVE

Alkermes cuts jobs in Ireland as Novartis invests

130 jobs to go at manufacturing facility in Athlone as Novartis creates 100 roles in Dublin

National Institute for Health and Care Excellence NICE logo

Clarity still needed on VBP as NICE adds social care to remit

Chief executive says DH will have to move quickly if the new drug reimbursement system is a “radically different” one

- PMLiVE

David Haslam takes over as NICE chair

Replaces Sir Michael Rawlins as body gains new social care responsibilities

- PMLiVE

Quality Standards – are we making the most of them?

As the UK health service enters a new chapter, NICE begins developing best practice guidelines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links